GlassScriptPhysician profile
Tiffany Andry
NPI 1316233067
$15,622.97
in general payments reported to CMS, 2019-2025
32 companies · $2,998 in 2025
The $2,998 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,574 · 2020: $1,249 · 2021: $1,432 · 2022: $2,403 · 2023: $2,320 · 2024: $2,648 · 2025: $2,998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,939 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,939.18 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $2,342.22 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $2,290.10 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Abbvie INC. | $1,397.89 | 2021-2025 | Vraylar |
| Alkermes, INC. | $1,322.98 | 2019-2023 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $1,086.42 | 2019-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $1,017.13 | 2020-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $778.10 | 2022-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $709.52 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Takeda Pharmaceuticals U.S.A., INC. | $696.47 | 2019-2025 | Trintellix |
| Ironshore Pharmaceuticals INC. | $595.49 | 2019 | |
| Lundbeck LLC | $517.33 | 2019-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $473.59 | 2020-2025 | Caplyta |
| Eisai INC. | $449.47 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $382.80 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $376.47 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $195.38 | 2019-2020 | |
| Dermira, INC. | $125.00 | 2019 | |
| Tris Pharma INC | $124.98 | 2024 | Quillichew Er, Quillivant, Dyanavel Xr |
| Corium, LLC | $121.56 | 2023-2024 | Azstarys |
| Neos Therapeutics, LP | $85.24 | 2020-2023 | Adzenys Xr-Odt |
| Idorsia Pharmaceuticals US INC | $84.55 | 2023 | Quviviq |
| Supernus Pharmaceuticals, INC. | $77.43 | 2022-2025 | Qelbree |
| Janssen Scientific Affairs, LLC | $63.65 | 2025 | Spravato |
| Noven Therapeutics, LLC | $59.55 | 2020-2024 | Secuado, Xelstrym |
| Bausch Health US, LLC | $58.33 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $52.75 | 2022-2023 | Belsomra |
| Sage Therapeutics, LLC | $42.27 | 2025 | Zurzuvae |
| Avanir Pharmaceuticals, INC. | $30.40 | 2019 | |
| Almatica Pharma LLC | $18.55 | 2022 | |
| Neuronetics, INC. | $17.96 | 2025 | Neurostar Tms Therapy System |
| Collegium Pharmaceutical, INC. | $15.76 | 2025 | Jornay Pm |
| Adlon Therapeutics L.P. | $13.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Andry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.